Header cover image
  • Investing Ideas
  • /
  • Australian Pharmaceuticals & Biotech Undervalued over 20% based on DCF

Australian Pharmaceuticals & Biotech Undervalued over 20% based on DCF

Results

2

1 new

Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.

2 companies

CSL

Market Cap: AU$128.3b

Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.

CSL

AU$267.20

7D

-1.8%

1Y

-11.6%

Medical Developments International

Market Cap: AU$64.2m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

New

MVP

AU$0.65

7D

-0.8%

1Y

65.4%